(Updates to include Lilly's comment in the fifth paragraph.)
Eli Lilly (LLY) closed up 3% Friday after media reports said US health officials are proposing a pilot program allowing Medicaid and some Medicare drug plans to cover costly weight loss medications.
The initiative would cover GLP-1 medicines for obesity, a category that includes Lilly's Zepbound, the reports said.
The pilot program for Medicaid may begin in April, with Medicare following in January 2027, the Washington Post reported, citing documents from the Centers for Medicare and Medicaid Services.
The proposal remains under review, the report said.
"Gaps in insurance coverage disrupt effective care and limit access to safe, evidence-based obesity management medications," a Lilly spokesperson said. "We are committed to working with payers and policymakers to expand coverage and improve care."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。